<DOC>
	<DOCNO>NCT02144103</DOCNO>
	<brief_summary>Autologous adipose-derived regenerative cell ( ADRC ) extract use Celution 800/CRS System ( Cytori Therapeutics Inc ) portion fat harvest patient 's front abdominal wall . ADRC administer one-time subtenon space patient 's eyeball . This single arm study control . All patient receive cell therapy .</brief_summary>
	<brief_title>Effectiveness Safety Adipose-Derived Regenerative Cells Treatment Glaucomatous Neurodegeneration</brief_title>
	<detailed_description>Fat tissue obtainment : Subjects undergo liposuction local anesthesia . In procedure , Ringer 's solution anesthetic lidocaine vasoconstrictor adrenaline infuse adipose compartment minimize blood loss contamination tissue peripheral blood cell . 15 minute later hollow blunt-tipped 3 mm cannula introduce subcutaneous space small ( 0.5 cm ) incision . The cannula attach syringe gentle suction move adipose compartment , mechanically disrupt fat tissue . Aspirate volume - approximately 150-200 cc . Procedure time - 30 minute . ADRC isolation : Aspirated fat tissue place sterile vessel insert Celution 800/CRS System ( Cytori Therapeutics Inc ) - closed system automate standardized extraction concentration ADRC . Celution 800/CRS System drain excess fluid fat tissue estimate 's volume After lipoaspirate wash extensively equal volume Ringer 's solution remove blood . At end process System indicate require volume enzyme reagent ( CelaseÂ® ) add immediately operator . After enzyme treatment Celution 800/CRS System automatically transfer isolate ADRC wash compartment ADRC wash concentrate 5 mL suspension . Tissue processing time - approximately 60 minute . ADRC suspension match requirement list technical documentation Celution 800/CRS System . Obtained ADRC divide 2 portion . First portion ( 0.2-0.5 mL ) use counting , viability sterility assessment . Second portion place sterile syringe injection . Subtenon injection ADRC : Antiseptic anesthetic solution instill conjunctival sac . After blepharostat instal . The patient ask look opposite injection side direction . Doctor insert needle inferior temporal quadrant rectus muscles,10-12 mm limbus . Needle move slowly , close possible eyeball . After needle placement depth 5-7 mm doctor injects concentrate solution ADRC ( 0,5 ml per single injection ) . Injection make insulin syringe needle size 0.45 mm * 12mm ( 26 G ) .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Retinal Degeneration</mesh_term>
	<criteria>Patient suffers primary openangle glaucoma ( II III stage ; singe eye eye ) least 6 month Intraocular pressure stable least 3 month Visual acuity eye ( measure use visual acuity chart projector ) less 0,1 Patient familiar Participant information sheet Patient sign informed consent form Noninclusion Criteria : Contraindications local anesthesia medical history allergic reaction local anesthetic Any anomaly condition least one eye limit tonometry implementation Inflammatory disease least one eye auxiliary apparatus ( infectious noninfectious etiology : conjunctivitis , keratitis , uveitis , dacryocystitis etc . ) Medical history surgery least one eye precede 6 month . Medical history heavy traumatic injury eye Patient cataract high degree lens opacification limit plan eye examination Patient prescribe systemic corticosteroid medication treatment proven effect lead intraocular pressure increase Medical history present dry eye syndrome accompany corneal conjunctival xerosis Subcompensated decompensated form chronic disease internal organ Clinically significant abnormality result laboratory test Any condition limit compliance ( dementia , neuropsychiatric disease , drug alcohol abuse etc . ) Participation clinical trial ( administration investigational drug ) 3 month prior inclusion Patients malignant tumor include postoperative period , patient receive chemotherapy and/or radiotherapy . Patient 's activate partial thromboplastin time exceed normal level 1,8 time Patients prescribed anticoagulant treatment patient receive anticoagulant least one hour prior lipoaspiration Medical history heterotopic ossification Patients prescribed glycoprotein inhibitor treatment Acute vascular pathology Agerelated macular degeneration Patient 's refusal participation trial Patient 's refusal compliance requirement contraception participation research Chronic kidney disease IV V stage ( creatinine clearance &lt; 30 mL/min estimate CockroftGault formula ) Confirmed syphilis , HIV , hepatitis B C infection Dropout Criteria : Direct indication immediate initiation treatment medication prove effect lead intraocular pressure increase Pregnancy Development cataract high degree lens opacification limit plan eye examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Glaucomatous Neurodegeneration</keyword>
	<keyword>Retinal Degeneration</keyword>
	<keyword>Primary Open-Angle Glaucoma</keyword>
	<keyword>Optic Neuropathy</keyword>
	<keyword>Intraocular pressure</keyword>
	<keyword>Retinal ganglion cell degeneration</keyword>
	<keyword>Optic nerve atrophy</keyword>
	<keyword>Subtenon injection</keyword>
	<keyword>Glaucomatous damage</keyword>
	<keyword>ADRC</keyword>
	<keyword>Adipose-derived regenerative cell</keyword>
	<keyword>Fat tissue</keyword>
	<keyword>Stem cell</keyword>
</DOC>